GenBody has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its nasal swab COVID-19 antibody test.
This is GenBody's second COVID-19 test to receive EUA from the FDA, the company said.
The company received a $10 million award from the U.S. National Institutes of Health under its Rapid Acceleration of Diagnostics initiative to increase COVID-19 testing capacity in the U.S.
GenBody's direct anterior nasal swab COVID-19 antigen test is the company's second test to receive FDA emergency use authorization. Image courtesy of GenBody.
